BNTX
Price
$109.00
Change
+$2.93 (+2.76%)
Updated
Jan 16 closing price
Capitalization
27.35B
51 days until earnings call
Intraday BUY SELL Signals
NVAX
Price
$8.01
Change
+$0.23 (+2.96%)
Updated
Jan 16 closing price
Capitalization
1.3B
45 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BNTX vs NVAX

Header iconBNTX vs NVAX Comparison
Open Charts BNTX vs NVAXBanner chart's image
BioNTech SE American Depositary Share
Price$109.00
Change+$2.93 (+2.76%)
Volume$1.19M
Capitalization27.35B
Novavax
Price$8.01
Change+$0.23 (+2.96%)
Volume$5.45M
Capitalization1.3B
BNTX vs NVAX Comparison Chart in %
View a ticker or compare two or three
VS
BNTX vs. NVAX commentary
Jan 18, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BNTX is a Hold and NVAX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 18, 2026
Stock price -- (BNTX: $109.00 vs. NVAX: $8.01)
Brand notoriety: BNTX: Not notable vs. NVAX: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BNTX: 94% vs. NVAX: 141%
Market capitalization -- BNTX: $27.35B vs. NVAX: $1.3B
BNTX [@Biotechnology] is valued at $27.35B. NVAX’s [@Biotechnology] market capitalization is $1.3B. The market cap for tickers in the [@Biotechnology] industry ranges from $111.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BNTX’s FA Score shows that 1 FA rating(s) are green whileNVAX’s FA Score has 1 green FA rating(s).

  • BNTX’s FA Score: 1 green, 4 red.
  • NVAX’s FA Score: 1 green, 4 red.
According to our system of comparison, both BNTX and NVAX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BNTX’s TA Score shows that 5 TA indicator(s) are bullish while NVAX’s TA Score has 5 bullish TA indicator(s).

  • BNTX’s TA Score: 5 bullish, 4 bearish.
  • NVAX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, BNTX is a better buy in the short-term than NVAX.

Price Growth

BNTX (@Biotechnology) experienced а +9.16% price change this week, while NVAX (@Biotechnology) price change was +10.18% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was +4.14%, and the average quarterly price growth was +42.40%.

Reported Earning Dates

BNTX is expected to report earnings on Mar 10, 2026.

NVAX is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (+1.24% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BNTX($27.4B) has a higher market cap than NVAX($1.3B). BNTX has higher P/E ratio than NVAX: BNTX (161.76) vs NVAX (3.99). NVAX YTD gains are higher at: 19.196 vs. BNTX (14.496). NVAX has higher annual earnings (EBITDA): 410M vs. BNTX (171M). BNTX has more cash in the bank: 14.5B vs. NVAX (763M). BNTX (245M) and NVAX (251M) have identical debt. BNTX has higher revenues than NVAX: BNTX (3.15B) vs NVAX (1.07B).
BNTXNVAXBNTX / NVAX
Capitalization27.4B1.3B2,104%
EBITDA171M410M42%
Gain YTD14.49619.19676%
P/E Ratio161.763.994,059%
Revenue3.15B1.07B296%
Total Cash14.5B763M1,900%
Total Debt245M251M98%
FUNDAMENTALS RATINGS
BNTX vs NVAX: Fundamental Ratings
BNTX
NVAX
OUTLOOK RATING
1..100
4316
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
75
Overvalued
PROFIT vs RISK RATING
1..100
97100
SMR RATING
1..100
91100
PRICE GROWTH RATING
1..100
4947
P/E GROWTH RATING
1..100
111
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NVAX's Valuation (75) in the Biotechnology industry is in the same range as BNTX (86) in the null industry. This means that NVAX’s stock grew similarly to BNTX’s over the last 12 months.

BNTX's Profit vs Risk Rating (97) in the null industry is in the same range as NVAX (100) in the Biotechnology industry. This means that BNTX’s stock grew similarly to NVAX’s over the last 12 months.

BNTX's SMR Rating (91) in the null industry is in the same range as NVAX (100) in the Biotechnology industry. This means that BNTX’s stock grew similarly to NVAX’s over the last 12 months.

NVAX's Price Growth Rating (47) in the Biotechnology industry is in the same range as BNTX (49) in the null industry. This means that NVAX’s stock grew similarly to BNTX’s over the last 12 months.

BNTX's P/E Growth Rating (1) in the null industry is in the same range as NVAX (11) in the Biotechnology industry. This means that BNTX’s stock grew similarly to NVAX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BNTXNVAX
RSI
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
86%
Momentum
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
79%
MACD
ODDS (%)
Bullish Trend 3 days ago
73%
N/A
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
69%
Bullish Trend 3 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
71%
Bullish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 5 days ago
72%
Bullish Trend 6 days ago
81%
Declines
ODDS (%)
N/A
Bearish Trend 4 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
BNTX
Daily Signal:
Gain/Loss:
NVAX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CSRE26.750.31
+1.16%
Cohen & Steers Real Estate Active ETF
FLMB23.910.01
+0.02%
Franklin Municipal Green Bond ETF
XDTE40.06-0.01
-0.04%
Roundhill S&P 500 0DTE Cov Cll Strat ETF
RDVI27.40-0.02
-0.07%
FT Vest Ris Div Ach Trg Inc ETF
MVAL38.05-0.35
-0.92%
VanEck Morningstar Wide Moat Value ETF

BNTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BNTX has been loosely correlated with SMMT. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if BNTX jumps, then SMMT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BNTX
1D Price
Change %
BNTX100%
+2.76%
SMMT - BNTX
53%
Loosely correlated
-1.33%
MRNA - BNTX
52%
Loosely correlated
+6.28%
KYMR - BNTX
44%
Loosely correlated
-2.22%
AXON - BNTX
43%
Loosely correlated
-0.18%
IMTX - BNTX
43%
Loosely correlated
-0.91%
More

NVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with MRNA. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then MRNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVAX
1D Price
Change %
NVAX100%
+2.96%
MRNA - NVAX
55%
Loosely correlated
+6.28%
BNTX - NVAX
43%
Loosely correlated
+2.76%
FHTX - NVAX
42%
Loosely correlated
-4.14%
CCCC - NVAX
39%
Loosely correlated
+0.45%
XNCR - NVAX
38%
Loosely correlated
-3.18%
More